BJL
FATE icon

Brighton Jones LLC’s Fate Therapeutics FATE Stock Holding History

Brighton Jones LLC’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.8K Buy
33,271
+18,834
+130% +$34.9K ﹤0.01% 1320
2026
Q1 		$17.3K Buy
+14,437
New +$17.6K ﹤0.01% 1190

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $3.05B AUM 42.78% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Brighton Jones LLC's FATE Position: Q2 2026 in Review

Brighton Jones LLC increased its Fate Therapeutics (FATE) stake by 130% in Q2 2026, buying an estimated $34.9K and bringing the position to 33,271 shares worth $89.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

Brighton Jones LLC first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Brighton Jones LLC held 33,271 shares of Fate Therapeutics worth $89.8K as of Q2 2026.
  • Brighton Jones LLC bought 18,834 Fate Therapeutics shares in Q2 2026, an estimated $34.9K.
  • Fate Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1320 holding.
  • Brighton Jones LLC first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.